6-Mercaptopurine phamacokinetics and blood lymphocyte subpopulations in patients with Crohn's disease treated with azathioprine;Dosage de la 6-mercaptopurine et etude des sous-populations lymphocytaires sanguines au cours du traitement par l'azathioprine dans la maladie de Crohn

Gastroenterologie Clinique et Biologique

Volumn 22, Issue 2, 1998, Pages 160-167

  Cattan, Stéphane ^a   Lémann, Marc ^a   Thuillier, François ^b   Bengoufa, Djaouida ^a   Rabian, Claire ^a   Ngo, Yann ^b   Bouhnik, Yoram ^b   Messing, Bernard ^b   Rambaud, Jean Claude ^b   Modigliani, Robert ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b Hopital Saint Lazare   (France)

Author keywords

6 mercaptopurine; Azathioprine; Blood lymphocyte subpopulations; Chronh's disease

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CROHN DISEASE; DRUG BLOOD LEVEL; DRUG EFFICACY; ENTERITIS; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE SUBPOPULATION; MALE; ORAL DRUG ADMINISTRATION; TREATMENT INDICATION; TREATMENT OUTCOME;

6-MERCAPTOPURINE; ADULT; AZATHIOPRINE; CROHN DISEASE; FEMALE; HUMANS; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE AGENTS; KINETICS; LYMPHOCYTE COUNT; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-2;

EID: 7144226572     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980; 302:981-7.
2. Lémann M, Bonhomme P, Bitoun A, Messing B, Modigliani R, Rambaud JC. Traitement de la maladie de Crohn par l'azathioprine ou la 6-mercaptopurine. Etude rétrospective chez 126 malades. Gastroenterol Clin Biol 1990;14:548-54.
3. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Pharmacol 1992;43:329-39.
4. Sandborn WJ, Van Os EC, Zins BJ, Tremainc WJ, Mays DC, Lipsky JJ. An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Gastroenterology 1995;109:1808-17.
5. Koren G, Ferrazini G, Sulh H, Langevin AM, Kapelushnik J, Klein J et al. Systemic exposure to mercaptopurine as a pronostic factor in acute lymphocytic leukemia in children. N Engl J Med 1990; 323:17-21.
6. Zimm S, Collins JM, Riccardi R, O'Neill D, Narang PK, Chabner B et al. Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered ? N Engl J Med 1983;308:1005-9.
7. Hayder S, Lafolie P, Björk O, Peterson C. 6-mercaptopurine plasma levels in children with acute lymphoblastic leukemia: relation to relapse risk and myelotoxicity. Ther Drug Monit 1989; 11:617-22.
8. Lilleyman JS, Lennard L. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukemia. Lancet 1994;343: 1188-90.
9. Colonna T, Korelitz BI. The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease. Am J Gastroenterol 1994;89:362-6.
10. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double-blind study of azathioprine in the management of Crohn's disease. Gut 1995;37:674-8.
11. D'Haens G, Callens J, Hiele M, Peeters M, Rutgeerts P. Reduction in neutrophil and not lymphocyte count is associated with favourable response to azathioprine therapy in refractory Crohn's disease (abstract). Gastroenterology 1995;108:A809.
12. Bernades P, Hecketsweiler P, Benozio M, Geffroy Y, Hemet J, Loygue J et al. Proposition d'un système de critères pour le diagnostic des entérocolites inflammatoires cryptogénétiques (maladie de Crohn et rectocolite hémorragique). Une étude coopérative du G.R.E.C. Gastroenterol Clin Biol 1978;2:1047-54.
13. Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn's disease activity index (CDAI). Gastroenterology 1979;77:843-6.
14. Narang P, Yeager R, Chatterji D. Quantification of 6-mercaptopurine in biological fluids using high-performance liquid chromatography: a selective and novel procedure. J Chromatography 1982;230:373-80.
15. Whalen CE, Tamary H, Greenberg M, Zipursky A, Soldin SJ. Analysis of 6-mercaptopurine in serum or plasma using high performance liquid chromatography. Ther Drug Monitor 1985;7: 315-20.
16. Czeuz R, Barnes P, Panayi GS. Natural killer cells in the blood of patients with rheumatoid arthritis treated with azathioprine. Br J Rheumatol 1990;29:284-7.
17. Prince H, Ettinger R, Dorey F, Fine R, Fahey J. Azathioprine suppression of natural killer activity and antibody-dependent cellular cytotoxicity in renal transplant patients. J Clin Immunol 1984;4:312-8.
18. Shin WW, Ellison GW, Myers LW, Durkos-Smith D, Fahey JL. Locus of selective depression of human natural killer cells by azathioprine. Clin Imnuinol Immunopathol 1982;23:672-81.
19. Campbell AC, Skinner JM, Mac Lennan IC, Hersey P, Waller CA, Wood J, et al. Immunosuppression in the treatment of inflammatory bowel disease. 2. The effects of azathioprine on lymphoid cell populations in a double blind trial in ulcerative colitis. Clin Exp Immunol 1976;24:249-58.
20. Leman B, Shanahan F, Targan S. Serial study of Immunologic alterations in patients with IBD on long term treatment with 6-MP: effect on TCL (abstract). Gastroenterology 1988;94:A255.
21. Leman B, Shanahan F. Deem R, Brogan M, Niederlehner A, Nayersina R et al. Enhanced non-MHC-restricted peripheral blood T cell cytotoxicity in inflammatory bowel disease (abstract). Gastroenterology 1987;92:A499.
22. Pallone F, Fais S, Squarcia O, Biancone L, Pozzilli P, Boirivant M. Activation of peripheral blood and intestinal lamina propria lymphocytes in Crohn's disease. In vivo state of activation and in vitro response to stimulation as defined by the expression of early activation antigens. Gut 1987;28:745-53.
23. Senju M, Hulstaert F, Lowder J, Jewell DP. Flow cytometric analysis of peripheral blood lymphocytes in ulcerative colitis and Crohn's disease. Gut 1991;32:779-83.
24. Ming RH, Aturu D, Spellman CW, Imir T, Goodwin JB, Strickland RG. Peripheral blood mononuclear-cell interleukine-2, receptor generation and lymphokine activated cytotoxicity in inflammatory bowel disease. J Clin Immunol 1987;7:59-63.
25. James SP, Neckers LM, Graeff AS, Cossman J, Balch CM, Strobcr W. Suppression of immunoglobulin synthesis by lymphocyte subpopulations in patients with Crohn's disease. Gastroenterology 1984;86:1510-4.
26. Raedler A, Fraenkel S, Klose G, Seyfarth K, Thiele G. Involvement of the immune system in the pathogenesis of Crohn's disease. Expression of the T9 antigen on peripheral immunocytes correlates with the severity of the disease. Gastroenterology 1985;88:978-83.
27. Crabtree JE, Duby LD, Heatley RV, Lobo AJ, Bullimore DW, Axon AT. Soluble interlcukin-2 receptor in Crohn's disease: relation of serum concentrations to disease activity. Gut 1990;31:1033-6.
28. Mueller Ch, Knoflach P, Zielinski CC. T-cell activation in Crohn's disease. Increased levels of soluble interleukin-2 receptor in serum and in supernatants of stimulated peripheral blood mononuclear cells. Gastroenterology 1990;98:639-46.
29. Mahida YR, Gallagher A, Kurlak L, Hawkey CJ. Plasma and tissue interleukin-2 receptor levels in inflammatory bowel disease. Clin Exp Immunol 1990;82:75-80.
30. Chan GL, Erdmann GR, Gruber SA, Stock P, Chen S, Ascher NL et al. Pharmacokinetics of 6-thiouric acid and 6-mercaptopurine in renal allograft recipients after oral administration of azathioprine. Eur J Clin Pharmacol 1989;36:265-71.
31. Lafolie P, Hayder S, Björk O, Peterson C. Intraindividual variation in 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute lymphoblastic leukemia. Eur J Clin Pharmacol 1991;40:599-601.
32. Sulh H, Koren G, Whalen C, Soldin S, Zipursky A, Greenberg M. Pharmacokinelic determinants of 6-mercaptopurine myelotoxicity and therapeutic failure in children with acute lymphoblastic leukemia. Clin Pharmacol Ther 1986;40:604-9.
33. Ohlman S, Albertioni F, Peterson C. Day-to-day variability in azathioprine pharmacokinetics in renal transplant recipients. Clin Transplantation 1994;8:217-23.
34. Liliemark J, Pettersson B, Lafolie P, Zweig T, Peterson C. Determination of plasma azathioprine and 6-mercaptopurine in patients with rheumatoid arthritis treated with oral azathioprine. Ther Drug Monitor 1990;12:339-43.
35. Zuccaro P, Guandalini S, Pacifici R, Pichini S, Di Martino L, Guidicci M, et al. Fat body mass and pharmacokinetics of oral 6-mercaptopurine in children with acute lymphoblastic leukemia. Ther Drug Monit 1991;13:37-41.
36. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989:46:149-54.
37. Bouhnik Y, Lémann M, Mary JY, Scemama G, Tai R, Matuchansky C, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996;347: 215-9.
38. Klemetsdal B, Wist E, Aarbakke J. Gender difference in red blood cell thiopurine methyltransferase activity. Scand J Clin Lab Invest 1993;53:747-9.
39. Lennard L, Welch J, Lilleyman JS. Intracellular metabolites of mercaptopurine in children with lymphoblastic leukaemia: a possible indicator of non-compliance. Br J Cancer; 1995:1004-6.
40. Chan GL, Erdmann GR, Gruber SA, Matas AJ, Canafax DM. Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiuouric acid and 6-thioguanine nucleotides in renal transplant patients. J Clin Pharmacol 1990;30:358-63.
41. Cuffari C, Seidman E, Théorêt Y. 6-mercaptopurine metabolite measurement in IBD patient's neutrophils correlates with drug efficacy (abstract). Gastroenterology 1995;108: A801.
42. Chocair PR, Duley JA, Simmonds HA, Cameron JS. The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation 1992;53:1051-6.
43. Lennard L, Davies HA, Lilleyman JS. Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukemia ? Br J Cancer 1993;68:186-90.
44. Cuffari C, Théorêt Y, Latour S, Seidman G. 6-mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996;39:401-6.